Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-01-30
2007-01-30
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S312000, C544S363000, C546S157000
Reexamination Certificate
active
10489647
ABSTRACT:
The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
REFERENCES:
patent: 5409930 (1995-04-01), Spada et al.
patent: 6306874 (2001-10-01), Fraley et al.
patent: 2003/0028018 (2003-02-01), Renhowe et al.
patent: WO 92/20642 (1992-11-01), None
patent: WO 97/06144 (1997-02-01), None
patent: WO 97/19927 (1997-06-01), None
patent: WO 97/44037 (1997-11-01), None
patent: WO 98/23613 (1998-06-01), None
patent: WO 00/09495 (2000-02-01), None
Emerging approaches to antiangiogenic therapies for treating cancer, posted Nov. 3, 2005 on http://www.nyas.org/ebriefreps/main.asp?intSubsectionID=3099 .
Chinese Science Bulletin, vol. 36, No. 24, pp. 2056-2060 (1991), by J. Meng, et al.
Science in China, vol. 36, No. 5, pp. 540-549 (1993), by J. Meng, et al.
Oncogene, vol. 6, pp. 1677-1683 (1991), by B. Terman, et al.
J. Clin. Invest, vol. 104, No. 11, pp. 1613-1620 (1991), by N. van Bruggen, et al.
Drug News Perspect, vol. 11, No. 5, pp. 265-270 (1998), by D. Greenberg.
Nature, vol. 407, pp. 242-248 (2000), by G. Yancopoulos, et al.
Nature, vol. 407, pp. 249-257 (2000), by P. Carmeliet, et al.
J. Heterocyclic Chem., vol. 28, pp. 1481-1484 (1991), by R. Wang, et al.
Nature Biotech., vol. 17, pp. 963-968 (1999), by V. Brower.
Nature Medicine, vol. 5, No. 6, pp. 623-628 (1999), by H. Gerber, et al.
Molecular Cell, vol. 4, pp. 915-924 (1999), by B. Eliceiri, et al.
Stem Cells, vol. 12, pp. 1-6 (1994), by T. Burke, Jr.
Platelets, vol. 10, pp. 285-292 (1999), by A Amirkhosravi, et al.
FEBS Letters, vol. 473, pp. 161-164 (2000), by M. Nakagawa, et al.
Endocrinology, vol. 141, No. 5 pp. 1667-1674 (2000), by M. Deckers, et al.
Oncogene, vol. 5, pp. 519-524 (1990), by M. Shibuya, et al.
J. Med. Chem., vol. 37, pp. 2129-2137 (1994), by M. Maguire, et al.
J. Med. Chem., vol. 42, pp. 5369-5389, by L. Hennequin, et al.
Cancer Research 64, pp. 751-756, Jan. 15, 2004, by L. Sepp-Lorenzino, et al.
Bioorganic & Medicinal Chemistry Letters 14, (2004), pp. 351-355, by M. Fraley, et al.
Current Medicinal Chemistry 11, (2004), pp. 709-719, by M. Fraley, et al.
Arrington Kenneth L.
Fraley Mark E.
Hartman George D.
Bernhardt Emily
Brown Dianne
Daniel Mark R.
Merck & Co. , Inc.
LandOfFree
Tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tyrosine kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3824379